A Phase 1/2 interventional study of ZGGS18 for Injection and ZGGS18 for Injection in Advanced Solid Tumor, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-05.
Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A clinical study to assess dose escalation, tolerance, safety, pharmacokinetics, and multi cohort expansion of ZGGS18 in patients with advanced solid tumors
Suzhou Zelgen Biopharmaceuticals Co.,Ltd is the lead sponsor of 83 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: ZGGS18 for Injection
Tumor type: colorectal cancer,pancreatic cancer
Biological: ZGGS18 for Injection
0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kgof ZGGS18,intravenous infusion, once every 2 weeks.
Recommended Phase 2 Dose (RP2D) (to be determined) of ZGGS18,intravenous infusion, once every 2 weeks.
Tolerability of ZGGS18
Dose limiting toxicity, number of participants with abnormal laboratory values and/or adverse events that are related to treatment
Time frame: 28 days
Safety of ZGGS18
Number of participants with adverse events/abnormal laboratory values that are related to treatment
Time frame: Through study completion, an expected average of 3 years
Pharmacokinetic characteristics of ZGGS18
Peak Plasma Concentration (Cmax)
Time frame: Through Phase I study completion, an expected average of 1 year
Pharmacokinetic characteristics of ZGGS18
Time to maximum concentration (Tmax)
Time frame: Through Phase I study completion, an expected average of 1 year
Pharmacokinetic characteristics of ZGGS18
Clearance (CL/F)
Time frame: Through Phase I study completion, an expected average of 1 year
Pharmacokinetic characteristics of ZGGS18
Area under drug concentration-time curve
Time frame: Through Phase I study completion, an expected average of 1 year
Pharmacokinetic characteristics of ZGGS18
Elimination rate constant (Ke)
Time frame: Through Phase I study completion, an expected average of 1 year
Pharmacokinetic characteristics of ZGGS18
Elimination half-life (t1/2)
Time frame: Through Phase I study completion, an expected average of 1 year
Immunogenicity of ZGGS18
Detection of anti-drug antibodies, if positive, further detection of neutralizing antibodies. Counting the number of patients and incidence of anti-drug antibodies and neutralizing antibodies
Time frame: Through study completion, an expected average of 3 years
Efficacy of ZGGS18
Objective response rate
Time frame: Through study completion, an expected average of 3 years
Efficacy of ZGGS18
Progression-free survival
Time frame: Through study completion, an expected average of 3 years
Efficacy of ZGGS18
Disease control rate
Time frame: Through study completion, an expected average of 3 years
Efficacy of ZGGS18
Duration of response
Time frame: Through study completion, an expected average of 3 years
Efficacy of ZGGS18
Time to response
Time frame: Through study completion, an expected average of 3 years
Efficacy of ZGGS18
Time to progression
Time frame: Through study completion, an expected average of 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for Nov 2026, 47 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Suzhou Zelgen Biopharmaceuticals Co.,Ltd →